{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:00:50Z","timestamp":1777780850757,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atten Disord"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:p>Objective: To compare the safety and efficacy of atomoxetine, a selective inhibitor of the norepinephrine transporter, versus placebo in Attention-Deficit\/Hyperactivity Disorder (ADHD) patients with comorbid Oppositional Defiant Disorder (ODD).<\/jats:p>\n                  <jats:p>Methods: A subset analysis of 98 children from two identical, multi-site, double-blind, randomized, placebo-controlled trials involving 9 weeks of treatment with atomoxetine or placebo was conducted. Patients met DSM-IV ADHD criteria. ODD was diagnosed with the Diagnostic Interview for Children and Adolescents-IV (DICA-IV; Reich, Welner, &amp; Herjanic, 1997). ADHD severity was assessed with the ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHD-RS-IV-Parent:Inv; DuPaul, Power, Anastopoulos, &amp; Reid, 1998); the short version of the Conners\u2019 Parent Rating Scales-Revised (CPRS-R:S; Conners, 2000); and the Clinical Global Impressions of ADHD Severity (CGI-ADHD-S; Guy, 1976). Clinical response was defined as a \u2265 25% reduction in ADHD-RS-IV-Parent:Inv total score.<\/jats:p>\n                  <jats:p>Results: ADHD-RS-IV-Parent:Inv, CGI-ADHD-S, and three CPRS-R:S subscale scores improved markedly with atomoxetine treatment. However, a decrease in the CPRS-R:S Oppositional subscore for atomoxetine-treated patients was not significantly greater than scores for placebo-treated patients. Clinical response rates were 65.4% in the atomoxetine group, and 36.4% in the placebo group ( p = .007).<\/jats:p>\n                  <jats:p>Conclusion: Atomoxetine was effective for the treatment of ADHD in patients with comorbid ODD. It did not significantly reduce the severity of ODD symptoms, and was well tolerated by the patients.<\/jats:p>","DOI":"10.1177\/108705470400800202","type":"journal-article","created":{"date-parts":[[2007,6,21]],"date-time":"2007-06-21T21:53:03Z","timestamp":1182462783000},"page":"45-52","source":"Crossref","is-referenced-by-count":49,"title":["Efficacy and safety of atomoxetine in childhood Attention-Deficit\/Hyperactivity Disorder with comorbid Oppositional Defiant Disorder"],"prefix":"10.1177","volume":"8","author":[{"given":"S.","family":"Kaplan","sequence":"first","affiliation":[{"name":"Penn State Hershey Medical Center, Hershey, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Heiligenstein","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"West","sequence":"additional","affiliation":[{"name":"Orlando, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Busner","sequence":"additional","affiliation":[{"name":"Penn State Hershey Medical Centre, Hershey, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Harder","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dittmann","sequence":"additional","affiliation":[{"name":"Lilly Deutschland GmbH, Bad Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Casat","sequence":"additional","affiliation":[{"name":"Carolinas Medical Center, Charlotte, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F.","family":"Wernicke","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2004,10,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.105.5.1158"},{"key":"atypb2","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000","edition":"4"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199910000-00015"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(02)00346-9"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0004.2000.580106.x"},{"key":"atypb6","volume-title":"Conners\u2019 Rating Scales-Revised (CRS-R)","author":"Conners, C.K.","year":"2000"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1016\/S0095-4543(08)70010-1"},{"key":"atypb8","volume-title":"ADHD Rating Scale-IV: Checklists, norms, and clinical interpretations","author":"DuPaul, G. J.","year":"1998"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.14.1100"},{"key":"atypb10","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy, W.","year":"1976"},{"key":"atypb11","volume-title":"Kiddie-SADS-Present and Lifetime Version (K-SADS-PL): The Department of Psychiatry","author":"Kaufman, J.","year":"1996"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830240023003"},{"key":"atypb13","volume-title":"Annual Meeting of the American Psychiatric Association","author":"Kratochvil, C."},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199712000-00020"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.11.1896"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.5.e83"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.12.1073"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200102000-00008"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1016\/S1056-4993(18)30109-3"},{"key":"atypb20","volume-title":"Diagnostic Interview for Children and Adolescents -IV (DICA-IV)","author":"Reich, W.","year":"1997"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1089\/10445460152595577"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1209"},{"key":"atypb23","volume-title":"Wechsler Intelligence Scale for Children (WISC-III)","author":"Wechsler, D.","year":"1991"},{"key":"atypb24","volume-title":"Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects","author":"World Medical Association","year":"2002"}],"container-title":["Journal of Attention Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/108705470400800202","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/108705470400800202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:27:28Z","timestamp":1777490848000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/108705470400800202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1177\/108705470400800202"],"URL":"https:\/\/doi.org\/10.1177\/108705470400800202","relation":{},"ISSN":["1087-0547","1557-1246"],"issn-type":[{"value":"1087-0547","type":"print"},{"value":"1557-1246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}